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ABSTRACT
Objectives: To evaluate endocan levels of patients with polycystic ovary syndrome (PCOS) in comparison to healthy women.
Material and methods: A cross-sectional case-control study on 88 patients with PCOS (mean age, 22.06 ± 4.24 years; 
body mass index [BMI], 23.9 ± 4.74 kg/m2) and 87 age- and BMI-matched healthy women (mean age, 23.71 ± 4.42 years; 
BMI, 22.15 ± 3.03 kg/m2). 
Results: Serum endocan level was significantly higher in PCOS group than control group (540.9 ± 280.3 pg/mL 
vs. 355.5 ± 233.5 pg/mL, respectively; p < 0.001). The presence of polycystic ovary finding on ultrasonography or oligome-
norhea did not produce significant effect on serum endocan levels (p > 0.05). In PCOS group, endocan level was negatively 
correlated with BMI and C-reactive protein level, and positively correlated with high density lipoprotein level (p < 0.05). 
Conclusions: Blood endocan level is increased in PCOS. Further studies are needed to evaluate the clinical value of blood 
endocan level as a marker for the risk of cardiovascular and metabolic diseases in patients with PCOS.
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INTRODUCTION
Polycystic ovary syndrome (PCOS) affects around 7% of 
women and is characterized by hyperandrogenism with or 
without oligo-anovulation [1]. The clinical signs and symp-
toms of PCOS change from puberty to perimenopausal 
period of patients. In addition to cosmetic complaints such 
as hirsutism and acne, patients with PCOS may have obesity, 
menstrual irregularity, and infertility. Increased levels of 
androgens in PCOS are associated with metabolic diseases 
including excess fat accumulation, obesity, and insulin re-
sistance [1]. 
In patients with PCOS, the risk of cardiovascular and 
metabolic diseases, primarily diabetes, has increased [2–6]. 
For this reason, it is important not only to manage PCOS in 
terms of patient’s specific complaints, but also to define 
potential risk of cardiovascular and metabolic diseases asso-
ciated with this syndrome, and to inform patients about this 
risk. Previous studies have reported an inflammatory pro-
cess underlying PCOS, which is associated with metabolic 
diseases, hyperandrogenism, insulin resistance, abdominal 
obesity, and endothelial damage [2–8]. Endothelium dys-
function, a chronic inflammatory process which is an early 
sign of atherosclerosis, has been demonstrated in studies 
on PCOS [8–10].
Endocan, endothelial cell-specific molecule (ESM-1), is 
a soluble 50 kDa molecular weight proteoglycan expressed 
in vascular endothelium [11]. It has been reported that en-
docan levels increase in many cancers, sepsis, obesity, and 
a variety of inflammatory pathologies by playing a critical 
role in vascular injury in organ-specific pathologies and 
being a potential novel marker in endothelium-dependent 
pathologic disorders [11, 12]. Although endothelial dysfunc-
tion in PCOS has been extensively studied, studies on the 
relationship between PCOS and endocan are limited [13, 14].
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Therefore, in this study, we aimed to evaluate endo-
can levels of patients with PCOS in comparison to healthy 
women in order to clarify the relationship between PCOS 
and endothelial injury.
MATERIAL AND METHODS
Study design and population
This was a cross-sectional case-control study conducted 
between January 2017 and April 2017 in the Department 
of Obstetrics and Gynecology, Gaziosmanpasa University 
Hospital, Tokat, Turkey. Eighty-eight patients with PCOS 
(mean age, 22.06 ± 4.24 years; body mass index [BMI], 
23.9 ± 4.74 kg/m2) and 87 age- and BMI-matched subjects 
(mean age, 23.71 ± 4.42 years; BMI, 22.15 ± 3.03 kg/m2) with 
normal menstrual cycles who presented to our outpatient 
clinic were included into the study. The selection criteria for 
the patients with PCOS were the absence of any signiﬁcant 
abnormalities on physical examination except hirsutism; 
no lipid lowering, hypoglycemic, antihypertensive or hor-
mone replacement therapy; normal thyroid function and 
prolactin level; absence of history or evidence of metabolic, 
cardiovascular, respiratory or hepatic disease. The diagnosis 
of PCOS was made in accordance with the criteria proposed 
at the Rotterdam revised consensus meeting (The Rotterdam 
European Society for Human Reproduction and Embryol-
ogy [ESHRE]/American Society for Reproductive Medicine 
[ASRM]-Sponsored PCOS Consensus Workshop Group, 2004) 
[15]. All eligible patients met at least 2 of the 3 following 
criteria: [a] oligomenorrhea or amenorrhea, [b] clinical and/ 
or biochemical signs of hyperandrogenism (hirsutism and 
acne), and [c] polycystic ovaries. Subjects with possible ovar-
ian tumors, congenital adrenal hyperplasia or BMI greater 
than 30 kg/m2 were excluded from the study. All patients 
and control subjects were non-smoker, normotensive (< 
120/80 mm Hg in two measurements), had regular daily ac-
tivity and not regular consumer of alcoholic beverages. None 
of the subjects were pregnant during the study procedures. 
The study was approved by the Clinical Research Ethics 
Committee of Gaziosmanpasa University School of Medicine 
(16-KAEK-038), and all patients and control subjects gave 
written informed consent before enrollment. The study was 
conducted according to the principles of the latest version 
of Helsinki Declaration. 
Study procedures
All the participants were evaluated in one study visit, 
during which data on medical history, physical examina-
tion including anthropometric measurements, laboratory 
test, and pelvic ultrasonography (US) were recorded. BMI 
(kg/m2) was used as an estimate of overall adiposity in both 
groups. To evaluate the severity of hirsutism, hirsutism score, 
which includes clinical signs of hyperandrogenism was used. 
A hirsutism score of more than 7 was considered as severe 
hirsutism [16]. The presence of PCO on US was recorded. 
All the measurements were made by the same physician. 
For laboratory tests, venous blood samples were 
drawn on the third to ﬁfth day of menstrual cycle between 
08:00 and 10:00 a.m. after a 12-hour fasting. Glucose, total 
cholesterol, triglyceride, high-density lipoprotein (HDL)-
cholesterol, and C-reactive protein (CRP) levels were meas-
ured by enzymatic colorimetric method using Olympus AU 
600 auto analyzer (Olympus Diagnostics, GmbH, Hamburg, 
Germany). Low-density lipoprotein (LDL)-cholesterol level 
was estimated by the Friedewald formula [LDL-cholester-
ol = (totalcholesterol)−(HDL-cholesterol)−(triglyceride/5)]. 
Luteinizing hormone (LH), follicle stimulant hormone (FSH), 
estradiol (E2), total testosterone, dehydroepiandrosterone 
sulphate (DHEA-S), and insulin were measured in serum by 
chemiluminescence, using Modular E-170 Immunologic 
Analyzer (Roche Diagnostics, Osaka, Japan). 
Blood endocan level measurements
The serum samples for endocan, i.e. ESM-1, were first 
stored for coagulation and then centrifuged for 15 min 
at 4000 xg at + 4°C. The serum samples obtained divided 
into aliquots and stored in a deep freeze at - 80˚C until 
analysis. ESM-1 levels in serum samples were measured 
using ELISA with a “Human ESM-1 ELISA Kit” (Elabscience 
Biotechnology Co. Ltd., Lot: AK0016DEC07042, Wuhan, 
China). It uses a double-antibody sandwich enzyme-linked 
immunosorbent assay. Samples like serum and standards 
were pipetted into the 96 well microplate being coated 
on with a monoclonal antibody (also known as Capture 
Antibody that is specific for C terminal of human ESM-1), 
and incubated for 90 min. ESM-1 present within a sample 
is bound by the Capture Antibody. After washing away of 
any unbound molecules, a secondary monoclonal antibody 
specific for N terminal of ESM-1 that has been biotinylated, 
was added to the wells to incubate for another 1 hour. After 
a washing step, streptavidin-HRP (biotin-binding protein 
conjugated with polymers of horseradish peroxidase) was 
added and allowed to incubate for 30 min. Unbound ma-
terial was washed away. Chromogen solution was added 
and incubated for 15 min (protected from light) for the 
conversion of the colorless solution to a blue solution, 
the intensity of which was proportional to the amount of 
ESM-1 in the sample. As an effect of the acidic stop solu-
tion, the color has become yellow. The colored reaction 
product was measured using an automated ELISA reader 
at 450 nm. The results were expressed as picograms per 
milliliter (pg/mL). The performance characteristics of this kit 
from the manifacturer’s sheet are given as: The measuring 
ranges, sensitivity, intra-assay precision and inter-assay pre-
cision of the endocan kit were 15.63 pg/mL to 1000 pg/mL, 
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9.375 pg/mL, < 8 and < 10 %, respectively. Values beneath 
the detection limit of 15.63 pg/mL were regarded as ‘0’.
Statistical analysis
The power analysis was performed using G Power 3.1 for 
Windows (Heinrich-Heine-Universität Düsseldorf, Düssel-
dorf, Germany) [17]. Sample size calculation was based on 
the mean endocan levels. Mean endocan levels were re-
ported as 621.82 ± 345.41 pg/mL and 391.40 ± 234.97 pg/mL 
in our pilot study. According to our pilot study results for 
circulating endocan levels, the minimum required size 
of the study population was calculated to be 70 subjects 
(α = 0.05 and the study power = 0.90).
Quantative data were summarized using mean and stand-
ard deviation. Independent samples t test or one way analysis 
of variance (ANOVA) test were used to compare normal data 
between groups. For post-hoc comparisons between the 
pair-wise groups, the Tukey HSD test was used. Mann Whit-
ney U test was used to compare non-normal data between 
groups. Pearson correlation coefficients were used to test 
inter-variable relationships. A p value < 0.05 was considered 
statistically significant. Analyses were performed using SPSS 
19 (IBM SPSS Statistics 19, SPSS Inc., Somers, NY, USA).
RESULTS
Clinical findings
The mean age of all the particants was 22.88 ± 4.40 years, 
and BMI was 23.03 ± 4.06 kg/m2. The frequency of PCO find-
ing on US, oligomenorrhea, and hyperandrogenism was 
73 (83.9%), 69 (78.4%), and 68 (77.3%), respectively. Age, 
BMI, and hirsutism score of PCOS patients were significantly 
higher than control group (p < 0.05) (Tab. 1). According to 
BMI, of all the study population, 32 (18.3%) and 15 (8.5%) 
were overweight (25–29.9 kg/m2) and obese (≥ 30 kg/m2), 
respectively. On the other hand, among PCOS patients, 
20 (22.7%) and 14 (15.9%) were overweight and obese, 
respectively.
Biochemical findings
Biochemical and hormonal proﬁles of the control group 
were within normal ranges. Among biochemical parameters, 
triglyceride, total cholesterol, LDL, fasting blood glucose and 
CRP were significantly higher in PCOS group compared to 
control group (p < 0.05) (Tab. 1). For hormonal parameters, 
LH, E2, DHEA-S and total testosterone were significantly 
higher in PCOS group compared to control group (p < 0.05), 
as FSH and TSH were comparable between groups (Tab. 1). 
Table 1. Distributions of variables in the study groups
Control group
(n = 87)
PCOS patients
(n = 88) p
Demographic and clinical findings
Age [years] 23.71 ± 4.42 22.06 ± 4.24 0.012a
BMI [kg/m2] 22.15 ± 3.03 23.9 ± 4.74 0.004a
Hirsutism score 0.39 ± 0.6 9.95 ± 4.23 < 0.001b
Hormonal parameters
FSH 5.59 ± 1.68 5.54 ± 1.9 0.830a
LH 8.2 ± 3.3 10.95 ± 7.47 0.002a
DHEA-S 92.62 ± 36.37 240.36 ± 122.01 < 0.001b
Total testosterone 0.06 ± 0.1 0.56 ± 0.28 < 0.001b
E2 59.99 ± 15.79 67.78 ± 69.51 0.037b
TSH 1.68 ± 0.58 1.82 ± 0.98 0.252a
Biochemical parameters
Fasting blood glucose 79.45 ± 6.6 88.66 ± 9.57 < 0.001a
Triglyceride 72.56 ± 12.75 110.28 ± 50.79 < 0.001a
Total cholesterol 106.3 ± 16.35 167.51 ± 32.22 0.001a
HDL 53.44 ± 3.66 51.64 ± 9.71 0.107a
LDL 90.13 ± 9.43 110.11 ± 25.14 < 0.001a
CRP 3.84 ± 1.6 5.33 ± 4.72 < 0.001b
Data are shown as mean ± standard deviation; a Independent Samples t test; 
b Mann Whitney U test; PCOS — polycystic ovary syndrome; BMI — body 
mass index; FSH — follicle stimulant hormone; LH — luteinizing hormone; 
DHEA-S — luteinizing hormone; E2 — estradiol; TSH — thyroid stimulating 
hormone; HDL — high-density lipoprotein; LDL — low-density lipoprotein; 
CRP — C-reactive protein
Table 2. Bivariate correlations of variables with endocan in all 
participants and PCOS and control groups
Endocan (pg/mL)
Total  
(n = 175)
PCOS group 
(n = 88)
Control group 
(n = 87)
BMI
r – 0.210 – 0.428 – 0.090
p 0.005 < 0.001 0.406
Hirsutism 
score
r 0.231 – 0.199 0.512
p 0.002 0.063 < 0.001
LH
r 0.229 0.186 0.128
p 0.002 0.083 0.237
DHEA-S
r 0.273 0.038 0.279
p < 0.001 0.723 0.009
Total 
testosterone
r 0.346 0.057 0.453
p < 0.001 0.597 < 0.001
Fasting blood 
glucose
r 0.328 – 0.007 0.559
p < 0.001 0.947 < 0.001
Total 
cholesterol
r 0.299 – 0.028 0.284
p < 0.001 0.799 0.008
HDL
r 0.158 0.392 – 0.309
p 0.037 < 0.001 0.004
CRP
r – 0.093 – 0.424 0.648
p 0.222 < 0.001 < 0.001
r denotes Pearson correlation coefficient; PCOS — polycystic ovary syndrome; 
BMI — body mass index; LH: luteinizing hormone; DHEA-S — luteinizing 
hormone; HDL — high-density lipoprotein; CRP — C-reactive protein
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oligomenorrhea did not affect the endocan level, suggest-
ing that there is no relation between imaging findings and 
menstrual symptoms of PCOS and endocan level. 
Endocan is a circulating endothelium-derived proteo-
glycan. An increase in tissue or blood endocan level shows 
endothelial activation and neovascularization, which are in-
dicators of inflammation and tumor progression [18]. There-
fore, blood endocan level has been used as a biomarker for 
various cancers including ovarian or endometrial carcinoma, 
pre-eclampsia, and inflammation-related diseases such as 
cirrhosis, sepsis, hypertension, and Behcet’s disease [18–24]. 
As well as presence and severity of inflammation-related 
diseases, these markers indicate cardiovascular and meta-
bolic risk of patients [25]. Furthermore, some studies pro-
posed endocan as a potential target for treatment of these 
diseases [26, 27]. 
It has been known that PCOS is a low-level chronic in-
flammation with increased serum level of inflammatory 
markers such as interleukin-1, interleukin-6, CRP, and tumor 
necrosis factor alpha [28, 29] Accordingly, in the present 
study biochemical and hormonal profiles of patients with 
PCOS showed significantly higher level of cardiovascular and 
inflamatory parameters regardless of PCO finding on US, 
oligomenorrhea, and BMI. The low-grade inflammation in 
PCOS is commonly associated with endothelial dysfunction 
regardless of BMI [30, 31]. Since increased level of circulat-
ing endocan is associated with endothelial dysfunction in 
Figure 1. The mean blood endocan level in study groups and with respect to PCO finding on US, oligomenorrhea, and BMI in PCOS group. Vertical 
bars represent standard deviation. PCO — polycystic ovary; US — ultrasonography; BMI — body mass index; PCOS — polycystic ovary syndrome
Serum endocan levels
Serum endocan level was significantly higher in 
PCOS group than control group (540.9 ± 280.3 pg/mL 
vs. 355.5 ± 233.5 pg/mL, respectively; p < 0.001) (Fig. 1). 
The presence of PCO finding on US and oligomenorrhea 
in PCOS group did not produce significant effect on blood 
endocan levels (p > 0.05) (Fig. 1). However, overweight and 
obese PCOS patients had significantly lower blood endo-
can levels than normal weight PCOS patients (p = 0.002) 
(Fig. 1).
As BMI and LH were not correlated with endocan levels 
in control group; hirsutism score, DHEA-S, total testosterone, 
fasting blood glucose, total cholesterol, and CRP were posi-
tively and HDL was negatively correlated with endocan lev-
els (Tab. 2). In PCOS group, there was a weak-to-moderate 
negative correlation between endocan levels and BMI and 
CRP, and positive correlation between endocan levels and 
HDL (Tab. 2).
DISCUSSION
In this case-control study, we primarily showed that 
serum endocan level is increased in patients with PCOS. 
Since BMI and CRP, the parameters related with inflamma-
tory process, were negatively correlated with blood endo-
can level, hormonal rather than inflammatory/endothelial 
changes of PCOS are implicated for the increase in circulat-
ing endocan level. The presence of PCO finding on US or 
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inflammatory conditions, which was suggested as an early 
sign of atherogenesis, endocan may have a potential role 
as a prognostic biomarker in PCOS and indicator of cardio-
vascular risk [32, 33]. 
In a recent study, Bicer et al. reported an increased level 
of circulating endocan levels in women with PCOS com-
pared with controls (5.99 ± 2.37 ng/mL vs. 3.66 ± 1.79 ng/mL, 
p < 0.001) [14]. Similarly, in our study, which is the sec-
ond study in the literature evaluating endocan level in 
PCOS, serum endocan level was significantly higher in 
PCOS group than the control group (540.9 ± 280.3 pg/mL 
vs. 355.5 ± 233.5 pg/mL, respectively; p < 0.001). 
Lean women populations with PCOS are a specific group 
and have different phenotypic, metabolic, and hematologic 
characteristics than obese women with PCOS and there is 
still an ongoing debate regarding this category of patients. It 
has been shown that obesity, and not PCOS status per se, 
was a major determinant of the circulating inflammatory 
markers TNF α, soluble type 2 TNF receptor, IL-6, and hs-CRP 
[34]. While the source of excess circulating TNF α in PCOS is 
likely to be adipose tissue in the obese but remains unknown 
in lean women with the disorder [35]. Therefore studies 
suggest that obesity is not independently associated with 
these markers of inflammation.
While they did not stratify PCOS subjects based on BMI, 
Bicer et al. also found that endocan is an independent pre-
dictor for carotid intima media thickness, which indicates 
risk of cardiovascular events, thus suggested that blood 
endocan level can be used to predict increased cardiovas-
cular risk in PCOS patients [14]. However, in our study we 
interestingly found that overweight and obese PCOS pa-
tients had significantly lower serum endocan levels than nor-
mal weight PCOS patients, and in PCOS group, there was 
a weak-to-moderate negative correlation between endo-
can levels and BMI and CRP, and positive correlation be-
tween endocan levels and HDL, indicating that endocan is 
not a direct marker of inflammation or cardiovascular risk 
in PCOS. We suggest that the increased endocan levels 
in lean PCOS patients compared to obese women with 
PCOS in our study may be explained by [1] the intracellular 
signalling pathways that govern the relationship between 
inflammatory response and circulating endocan levels may 
be more impaired in lean women with PCOS than obese 
women with PCOS or [2] endocan production may be re-
garded as part of a protective mechanism in the crosstalk 
of multiple signalling mediators, fighting with the state of 
increased inflammation. We think our study contributes to 
our understanding on the presence of PCOS in lean women 
while future studies in this field should define the Rotterdam 
phenotype of subjects, stratify subjects based on BMI, use 
clinically relevant cut offs rather than comparison of means 
and ultimately provide longitudinal data on changes in 
biomarkers and their correlation with metabolic and clinical 
manifestations of PCOS.
 Furthermore, in our study the presence of PCO finding 
on ultrasonography and oligomenorrhea in PCOS group 
did not produce significant effect on serum endocan lev-
els. Therefore, we suggest that there is no relation between 
symptoms of PCOS and endocan level. On the other hand, 
in control group of women with normal menstrual cyles; 
hirsutism score, DHEA-S, total testosterone, fasting blood 
glucose, total cholesterol, and CRP were positively and HDL 
was negatively correlated with endocan levels. 
The main limitation of our study was its cross-sectional 
design, which limits the interpretation of cause-effect re-
lation of increased level of circulating endocan level and 
PCOS. Nevertheless, this is among the few studies on the 
blood endocan level in patients with PCOS. Further studies 
are needed to clarify the exact mechanism underlying the 
increase in blood endocan level in PCOS.
CONCLUSIONS
Serum endocan level is increased in patients with PCOS, 
which seems to result from hormonal or other factors which 
need to be evaluated rather than inflammatory/endothelial 
changes of PCOS. Further studies are needed to conclude 
on mechanism of increased endocan level in PCOS, and to 
evaluate the clinical value of endocan as a biomarker for 
inflammation and cardiovascular risk, and potential thera-
peutic target in PCOS.
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